These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 25322077

  • 1. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP, Marek KL.
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [Abstract] [Full Text] [Related]

  • 2. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
    Russell DS, Jennings DL, Barret O, Tamagnan GD, Carroll VM, Caillé F, Alagille D, Morley TJ, Papin C, Seibyl JP, Marek KL.
    Neurology; 2016 Feb 23; 86(8):748-54. PubMed ID: 26802091
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington's disease.
    Bertoglio D, Verhaeghe J, Kosten L, Thomae D, Van der Linden A, Stroobants S, Wityak J, Dominguez C, Mrzljak L, Staelens S.
    PLoS One; 2018 Feb 23; 13(10):e0206613. PubMed ID: 30365550
    [Abstract] [Full Text] [Related]

  • 6. In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [18F]MNI-659.
    Svedberg MM, Varnäs K, Varrone A, Mitsios N, Mulder J, Gulyás B, Beaumont V, Munoz-Sanjuan I, Zaleska MM, Schmidt CJ, Halldin C, Mrzljak L.
    Brain Res; 2019 May 15; 1711():140-145. PubMed ID: 30664847
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
    Fazio P, Fitzer-Attas CJ, Mrzljak L, Bronzova J, Nag S, Warner JH, Landwehrmeyer B, Al-Tawil N, Halldin C, Forsberg A, Ware J, Dilda V, Wood A, Sampaio C, Varrone A, PEARL-HD and LONGPDE10 study collaborators.
    Mov Disord; 2020 Apr 15; 35(4):606-615. PubMed ID: 31967355
    [Abstract] [Full Text] [Related]

  • 10. Early grey matter changes in structural covariance networks in Huntington's disease.
    Coppen EM, van der Grond J, Hafkemeijer A, Rombouts SA, Roos RA.
    Neuroimage Clin; 2016 Apr 15; 12():806-814. PubMed ID: 27830113
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, TRACK-HD investigators.
    Lancet Neurol; 2012 Jan 15; 11(1):42-53. PubMed ID: 22137354
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.